SKIN RASH TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Skin Rash Treatment Market, By Treatment Type (Corticosteroids, Immunosuppressants, Antihistamines, Antifungals, and Others), By Skin Rash Type (Contact Dermatitis, Atopic Dermatitis (Eczema), Psoriasis, Seborrheic Dermatitis, and Others), By Distribution Channel (Pharmacies, Retail Stores, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

In May 2022, Dermavant Sciences, a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. This approval makes VTAMA cream the first and only FDA-approved steroid-free topical medication in its class.
In June 2022, Galderma, a pharmaceutical company specializing in dermatological treatments announced the availability of EPSOLAY (benzoyl peroxide) Cream, 5% in the U.S. following approval by the U.S. Food and Drug Administration (FDA)
In September 2022, Regeneron Pharmaceuticals, Inc., a biotechnology company and Sanofi, a multinational pharmaceutical and healthcare company announced that the U.S. Food and Drug Administration (FDA) had approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis

Skin Rash Treatment Market Report Snapshots